Endres CJ - Search Results

1

Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.

Suri A, Mould DR, Song G, Collins GP, Endres CJ, Gomez-Navarro J, Venkatakrishnan K. Suri A, et al. Among authors: endres cj. Clin Pharmacol Ther. 2019 Dec;106(6):1268-1279. doi: 10.1002/cpt.1530. Epub 2019 Jul 9. Clin Pharmacol Ther. 2019. PMID: 31152605 Free PMC article. Clinical Trial.

2

Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective.

Li C, Menon R, Walles M, Singh R, Upreti VV, Brackman D, Lee AJ, Endres CJ, Kumar S, Zhang D, Barletta F, Suri A, Hainzl D, Liao KH, Lalovic B, Beaumont M, Zuo P, Mayer AP, Wei D. Li C, et al. Among authors: endres cj. Clin Pharmacol Ther. 2022 Oct;112(4):754-769. doi: 10.1002/cpt.2448. Epub 2021 Nov 23. Clin Pharmacol Ther. 2022. PMID: 34657311

3

The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes.

Endres CJ, Moss AM, Ke B, Govindarajan R, Choi DS, Messing RO, Unadkat JD. Endres CJ, et al. J Pharmacol Exp Ther. 2009 Apr;329(1):387-98. doi: 10.1124/jpet.108.145854. Epub 2009 Jan 22. J Pharmacol Exp Ther. 2009. PMID: 19164463 Free PMC article.

4

The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice.

Endres CJ, Moss AM, Govindarajan R, Choi DS, Unadkat JD. Endres CJ, et al. J Pharmacol Exp Ther. 2009 Oct;331(1):287-96. doi: 10.1124/jpet.109.153130. Epub 2009 Jul 14. J Pharmacol Exp Ther. 2009. PMID: 19602549 Free PMC article.

5

Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.

Endres CJ, Salinger DH, Köck K, Gastonguay MR, Martin DA, Klekotka P, Nirula A, Gibbs MA. Endres CJ, et al. J Clin Pharmacol. 2014 Nov;54(11):1230-8. doi: 10.1002/jcph.334. Epub 2014 May 27. J Clin Pharmacol. 2014. PMID: 24846347 Clinical Trial.

6

Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.

Topletz-Erickson AR, Lee AJ, Mayor JG, Rustia EL, Abdulrasool LI, Wise AL, Dailey B, DeChenne S, Walker LN, Alley SC, Endres CJ. Topletz-Erickson AR, et al. Among authors: endres cj. J Clin Pharmacol. 2021 Apr;61(4):461-471. doi: 10.1002/jcph.1750. Epub 2020 Sep 28. J Clin Pharmacol. 2021. PMID: 32989831 Free PMC article. Clinical Trial.

7

A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.

Salinger DH, Endres CJ, Martin DA, Gibbs MA. Salinger DH, et al. Among authors: endres cj. Clin Pharmacol Drug Dev. 2014 Jul;3(4):276-83. doi: 10.1002/cpdd.103. Epub 2014 Feb 18. Clin Pharmacol Drug Dev. 2014. PMID: 27128833 Clinical Trial.

8

Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. Dong JQ, et al. Among authors: endres cj. Clin Pharmacokinet. 2011 Feb;50(2):131-42. doi: 10.2165/11537430-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21241072

9

Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl.

Sun H, Cardinal KA, Wienkers L, Chin A, Kumar V, Neace C, Henderson C, Endres CJ, Topletz-Erickson A, Regal K, Vo A, Alley SC, Lee AJ. Sun H, et al. Among authors: endres cj. Cancer Chemother Pharmacol. 2022 Jun;89(6):737-750. doi: 10.1007/s00280-022-04429-z. Epub 2022 Apr 18. Cancer Chemother Pharmacol. 2022. PMID: 35435471

10

Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.

Topletz-Erickson A, Lee A, Rustia EL, Sun H, Mayor JG, Abdulrasool LI, Walker L, Endres CJ. Topletz-Erickson A, et al. Among authors: endres cj. Clin Pharmacokinet. 2022 Oct;61(10):1417-1426. doi: 10.1007/s40262-022-01144-z. Epub 2022 Aug 6. Clin Pharmacokinet. 2022. PMID: 35931943 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page